Ceapro
Ceapro Inc. is a Canadian biotech company that develops and supplies proprietary oat-derived bioactive ingredients — including avenanthramides, beta-glucans, oat flour, and oat oil — to global cosmetics, personal care, nutraceutical, and pharmaceutical manufacturers from its GMP facility in Edmonton.
- Company typePublic
- Founded1994
- HeadquartersEdmonton, Canada
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Ceapro does
Ceapro Inc. is a Canadian biotechnology company founded in 1994 and headquartered in Edmonton, Alberta, that develops and manufactures premium, science-backed bioactive ingredients derived primarily from oats for the cosmetics, personal care, nutraceutical, and pharmaceutical industries. Its product portfolio consists of four core ingredients — CP Oat Avenanthramide Extract (anti-irritant/antioxidant), CP Oat Beta Glucan (moisturizing, skin-repairing, GRAS-approved for nutraceuticals), CP Oat Flour Superfine/Colloidal Oatmeal, and Oat Oil (barrier restoration) — all produced from elite North American oat varieties under exclusive supply arrangements that provide complete farm-to-finished-extract traceability.
The company's technical platform rests on three proprietary processes: ethanol fractionation, chromatography purification, and Pressurized Gas Expanded (PGX) technology, all operated within a 30,000 sq. ft. GMP-certified bio-processing facility that integrates R&D, pilot, and commercial-scale production. Certifications include EcoCert, Non-GMO, Gluten-Free, Allergen-Free, Fragrance-Free, and Not-Tested-on-Animals, which together support premium positioning with global cosmetics megabrands. Ceapro is extending PGX into pharmaceutical-grade applications, notably yeast beta glucan for immune-boosting clinical trials, funded in part by Canadian federal grants.
Commercially, Ceapro operates a B2B ingredients model with quote-based pricing, direct enterprise sales to global megabrands, and a website-driven sample-request funnel as the primary lead capture mechanism. The company is publicly traded (OTCMKTS: CRPOF; CVE: CZO) and operates as a subsidiary of Cosciens Biopharma. Revenue is concentrated in the single-digit millions (~$7M in 2023), the company is currently unprofitable with a –69.6% net margin, and the customer base is qualitatively described as "global megabrands" without disclosed specific logos.
Ceapro firmographics
Firmographics- Name
- Ceapro
- Legal name
- Ceapro Inc.
- Website
- https://ceapro.com
- Company type
- Public
- Founded year
- 1994
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Ceapro Inc. is a Canadian biotech company that develops and supplies proprietary oat-derived bioactive ingredients — including avenanthramides, beta-glucans, oat flour, and oat oil — to global cosmetics, personal care, nutraceutical, and pharmaceutical manufacturers from its GMP facility in Edmonton.
- Ownership category
- akta.pro rank
Ceapro industry classification
Industry- Product category
- Natural Bio-active Cosmetic Ingredients
- NAICS
- Fruit and Vegetable Preserving and Specialty Food Manufacturing (3114), Starch and Vegetable Fats and Oils Manufacturing (31122)
- SIC
- Medicinal Chemicals & Botanical Products (2833), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Fortification Ingredients (Vitamins, Minerals, Nutrient Premixes) (CRADAOAM)
Keywords
Where Ceapro is headquartered
LocationHeadquarters
- HQ city
- Edmonton
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
Ceapro business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales
Revenue model
- Oat-derived Bio-active Ingredients: Sale of proprietary oat-derived bio-active ingredients including CP Oat Avenanthramide Extract, CP Oat Beta Glucan, CP Oat Flour Superfine, and Oat Oil to cosmetics, personal care, and nutraceutical manufacturers. Revenue is generated through product sales with pricing based on volume and specification requirements.
- Pharmaceutical Ingredients: Development of pharmaceutical-grade active pharmaceutical ingredients (APIs) including yeast beta glucan for clinical trials related to immune-boosting and COVID-19 conditions through their PGX technology.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Ceapro product offering
Product offeringCore offering
Ceapro Inc. develops and manufactures premium, science-backed natural bio-active ingredients derived from oats (Avena sativa), including avenanthramide extract, beta glucan, colloidal oatmeal, and oat oil. These ingredients are produced using proprietary green bioprocessing technologies at a 30,000 sq. ft. GMP-certified facility in Edmonton, Alberta, and are supplied to cosmetics, personal care, nutraceutical, and pharmaceutical manufacturers worldwide.
Product overview
Ceapro is a Canadian biotech company that develops and manufactures premium, science-backed natural oat-derived bioactive ingredients for the cosmetics, personal care, and nutraceutical industries. The product portfolio consists of four core products: CP Oat Avenanthramide Extract (anti-irritant and antioxidant), CP Oat Beta Glucan (moisturizing and skin-repairing, GRAS approved for nutraceuticals), CP Oat Flour Superfine/Colloidal Oatmeal (exfoliation and soothing), and Oat Oil (skin barrier restoration and nourishment). These ingredients are produced using proprietary extraction and processing technologies including Ethanol Fractionation Processes, Chromatography Purification, and Pressurized Gas Expanded (PGX) technology, all manufactured in the company's GMP-certified facility.
Differentiator
Problem solved
Functional benefit
Products and services
- CP Oat Avenanthramide Extract
Quantifiable outcome
- 30+ years of continuous operation and research in oat-derived ingredients
- +1 more outcomes
Companies that use Ceapro
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
Ceapro technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Ceapro partnerships and signals
Strategic signalScale indicators5 records
Recent moves6 records
Expansion highlights4 records
Ceapro competitors and assessment
Company assessmentBroad incumbents
- dsm-firmenich: Global specialty ingredients major formed by the merger of DSM and Firmenich, with a large Personal Care & Aroma and Nutrition segments. Directly comparable to Ceapro as a B2B supplier of scientifically validated bioactive ingredients to cosmetics, personal care, and nutraceutical megabrands, though vastly larger in scale and breadth.
- BASF Care Creations: BASF's personal care specialty ingredients arm supplies bioactives, emollients, and actives to global cosmetic brands. Overlaps directly with Ceapro's ingredient portfolio (oat-derived emollients and bioactives), but as part of a much broader chemicals and ingredients conglomerate.
Direct peers
- Evonik Personal Care: Specialty silica, ceramide, and bioactive specialty ingredients for skin and hair care. Direct competitor in the cosmetic actives space with comparable scientific positioning and B2B sales motion into the same global megabrands Ceapro serves.
- Givaudan Active Beauty: Givaudan's Active Beauty business supplies cosmetic bioactive ingredients (antioxidants, skin-conditioning actives) to global personal care brands. Closely comparable to Ceapro's positioning in science-backed, naturally sourced cosmetic actives, though Givaudan offers a much broader portfolio and global service network.
Peers
Market position
Strengths2 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Ceapro social profiles
Digital presenceCeapro compliance and trust
Trust signalCompliance5 records
Ceapro financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ceapro leadership team
Management profileNumber of profiles
Profiles5 records
Ceapro funding detail
Funding detailFunding overview
Funding rounds4 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ceapro M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ceapro
What does Ceapro do?
Ceapro Inc. develops and manufactures premium, science-backed natural bio-active ingredients derived from oats (Avena sativa), including avenanthramide extract, beta glucan, colloidal oatmeal, and oat oil. These ingredients are produced using proprietary green bioprocessing technologies at a 30,000 sq. ft. GMP-certified facility in Edmonton, Alberta, and are supplied to cosmetics, personal care, nutraceutical, and pharmaceutical manufacturers worldwide.
Is Ceapro a public or private company?
Ceapro is a public company. It is classified as public and is currently operating.
When was Ceapro founded?
Ceapro was founded in 1994. It employs 11 to 50 people.
Where is Ceapro based?
Ceapro is headquartered in Edmonton, Canada, in the North America region.
How does Ceapro make money?
Two revenue lines are on record. Oat-derived Bio-active Ingredients are the primary driver. The others are pharmaceutical Ingredients.
Who are Ceapro's main competitors?
Broad incumbents on record are dsm-firmenich and BASF Care Creations. Direct peers are Evonik Personal Care and Givaudan Active Beauty. Symrise (Cosmetic Ingredients) is listed as a peer.
Does Ceapro have an API?
No public API is recorded for Ceapro.
What industry is Ceapro in?
Ceapro's product category is Natural Bio-active Cosmetic Ingredients. Its primary akta.pro industry code is CRADAOAM, Fortification Ingredients (Vitamins, Minerals, Nutrient Premixes). Its NAICS code is 3114 and its SIC code is 2833.